{"id":2361,"date":"2014-09-19T11:54:54","date_gmt":"2014-09-19T11:54:54","guid":{"rendered":"https:\/\/medicalcriteria.com\/web\/onckho\/"},"modified":"2026-04-08T20:13:38","modified_gmt":"2026-04-08T20:13:38","slug":"onckho","status":"publish","type":"post","link":"https:\/\/medicalcriteria.com\/web\/onckho\/","title":{"rendered":"Modified Khorana Risk Score for Prediction of Venous Thromboembolic Events (VTE) in Patients with Cancer"},"content":{"rendered":"<div class=\"99c380e4b4a7b96c35d7ddf7dcb434e8\" data-index=\"1\" style=\"float: none; margin:0px 0 0px 0; text-align:center;\">\n<script async src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js\"><\/script>\r\n<!-- MC 2019- Horizontal -->\r\n<ins class=\"adsbygoogle\"\r\n     style=\"display:block\"\r\n     data-ad-client=\"ca-pub-0127150553352455\"\r\n     data-ad-slot=\"3806776041\"\r\n     data-ad-format=\"auto\"\r\n     data-full-width-responsive=\"true\"><\/ins>\r\n<script>\r\n     (adsbygoogle = window.adsbygoogle || []).push({});\r\n<\/script>\n<\/div>\n<p>Risk assessment tools can incorporate multiple variables to identify\u00a0patients or subpopulations at risk for events. A recently developed\u00a0risk score can identify cancer patients at high risk for VTE using a\u00a0combination of easily available clinical and laboratory variables.<br \/>\n<!--more--><br \/>\n<strong>Modified Khorana Risk Score for Prediction of Venous Thromboembolic Events (VTE)\u00a0<\/strong><strong>in Patients with Cancer<\/strong><\/p>\n<table style=\"border-collapse: collapse; width: 100%; height: 201px;\" border=\"1\">\n<tbody>\n<tr style=\"height: 24px;\" valign=\"TOP\">\n<td style=\"height: 24px;\" width=\"467\"><strong>Patient Characteristic<\/strong><\/td>\n<td style=\"height: 24px; text-align: center;\" width=\"158\"><strong>Points<\/strong><\/td>\n<\/tr>\n<tr style=\"height: 48px;\" valign=\"TOP\">\n<td style=\"height: 31px;\" width=\"467\">Site of cancer:\u00a0Very high risk (stomach, pancreas, primary\u00a0brain tumor)<\/td>\n<td style=\"height: 31px; text-align: center;\" width=\"158\">2<\/td>\n<\/tr>\n<tr style=\"height: 48px;\" valign=\"TOP\">\n<td style=\"height: 48px;\" width=\"467\">Site of cancer:\u00a0High risk (lung, lymphoma, gynecologic,\u00a0bladder, testicular, renal tumors)<\/td>\n<td style=\"height: 48px; text-align: center;\" width=\"158\">1<\/td>\n<\/tr>\n<tr style=\"height: 48px;\" valign=\"TOP\">\n<td style=\"height: 24px;\" width=\"467\">Pre-chemotherapy platelet count \u00a0350,000\/\u00b5L or more<\/td>\n<td style=\"height: 24px; text-align: center;\" width=\"158\">1<\/td>\n<\/tr>\n<tr style=\"height: 48px;\" valign=\"TOP\">\n<td style=\"height: 26px;\" width=\"467\">Hemoglobin level &lt;10 g\/dL or use of red-cell growth factors<\/td>\n<td style=\"height: 26px; text-align: center;\" width=\"158\">1<\/td>\n<\/tr>\n<tr style=\"height: 24px;\" valign=\"TOP\">\n<td style=\"height: 24px;\" width=\"467\">Prechemotherapy leukocyte count \u00a0&gt;11,000\/\u00b5L<\/td>\n<td style=\"height: 24px; text-align: center;\" width=\"158\">1<\/td>\n<\/tr>\n<tr style=\"height: 24px;\" valign=\"TOP\">\n<td style=\"height: 24px;\" width=\"467\">Body mass index \u00a035 kg\/m2 or more<\/td>\n<td style=\"height: 24px; text-align: center;\" width=\"158\">1<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Calculate total score, adding points for each\u00a0criterion in the model.<br \/>\nInterpretation:<\/p>\n<ul>\n<li>High risk \u00a0&gt;\/= 3 points<\/li>\n<li>Intermediate risk, 1 to 2 points<\/li>\n<li>Low risk, 0 points<\/li>\n<\/ul>\n<p>Abbreviation: VTE, venous thromboembolism.<\/p>\n<p>&nbsp;<\/p>\n<p><strong>References:<\/strong><\/p>\n<ol>\n<li>Lyman GH, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, Clarke JM, Flowers CR, Francis CW, Gates LE, Kakkar AK, Key NS, Levine MN, Liebman HA, Tempero MA, Wong SL, Prestrud AA, Falanga A; American Society of Clinical Oncology Clinical Practice.\u00a0Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013 Jun 10;31(17):2189-204.\u00a0<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/23669224\/\" target=\"_blank\" rel=\"noopener noreferrer\">[Medline]<\/a><\/li>\n<li>Khorana AA, McCrae KR. Risk stratification strategies for cancer-associated thrombosis: an update. Thromb Res. 2014 May;133 Suppl 2:S35-8. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/24862143\/\" target=\"_blank\" rel=\"noopener noreferrer\">[Medline]<\/a><\/li>\n<li>Gomes M, Khorana AA. Risk assessment for thrombosis in cancer. Semin Thromb Hemost. 2014 Apr;40(3):319-24.\u00a0<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/24599438\/\" target=\"_blank\" rel=\"noopener noreferrer\">[Medline]<\/a><\/li>\n<li>Fowler C, Pastores SM. Venous Thromboembolic Events in Cancer Immunotherapy: A Narrative Review. J Clin Med. 2025 Jul 11;14(14):4926. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/40725619\/\" target=\"_blank\" rel=\"noopener\">[Medline]<\/a><\/li>\n<\/ol>\n<p>&nbsp;<\/p>\n<p>Created Sep 19, 2014.<br \/>\nUp-date Apr 08, 2026.<\/p>\n\n<div style=\"font-size: 0px; height: 0px; line-height: 0px; margin: 0; padding: 0; clear: both;\"><\/div>","protected":false},"excerpt":{"rendered":"<p>Sorry, this entry is only available in Espa\u00f1ol.<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"no","_lmt_disable":"no","_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":""},"categories":[272],"tags":[896,897,669,428,767,450,898,899],"class_list":["post-2361","post","type-post","status-publish","format-standard","hentry","category-oncology","tag-events","tag-khorana","tag-modified","tag-prediction","tag-risk","tag-score","tag-thromboembolic","tag-venous"],"modified_by":"Guillermo Firman","_links":{"self":[{"href":"https:\/\/medicalcriteria.com\/web\/wp-json\/wp\/v2\/posts\/2361","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicalcriteria.com\/web\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicalcriteria.com\/web\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicalcriteria.com\/web\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/medicalcriteria.com\/web\/wp-json\/wp\/v2\/comments?post=2361"}],"version-history":[{"count":5,"href":"https:\/\/medicalcriteria.com\/web\/wp-json\/wp\/v2\/posts\/2361\/revisions"}],"predecessor-version":[{"id":10738,"href":"https:\/\/medicalcriteria.com\/web\/wp-json\/wp\/v2\/posts\/2361\/revisions\/10738"}],"wp:attachment":[{"href":"https:\/\/medicalcriteria.com\/web\/wp-json\/wp\/v2\/media?parent=2361"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicalcriteria.com\/web\/wp-json\/wp\/v2\/categories?post=2361"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicalcriteria.com\/web\/wp-json\/wp\/v2\/tags?post=2361"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}